Effects of Tauroursodeoxycholic Acid and 4-Phenylbutyric Acid on Selenium Distribution in Mice Model with Type 1 Diabetes

Abstract

The effect of selenium on diabetes is significant. As pharmaceutical chaperones, tauroursodeoxycholic acid (TUDCA) and 4-phenylbutyric acid (4-PBA) can effectively improve the oxidative stress of the endoplasmic reticulum. This study established a mice model with type 1 diabetes (T1D) to evaluate the effects of pharmaceutical chaperones on selenium distribution. Streptozotocin was used to induce Friend virus B-type mice to establish a T1D mice model. Mice were administered with TUDCA or 4-PBA. Selenium levels in different tissues were measured by inductively coupled plasma-mass spectroscopy (ICP-MS). After treatment with TUDCA and 4-PBA, related laboratory findings such as glucose and glycated serum protein were significantly reduced and were closer to normal levels. At 2 weeks, 4-PBA normalized selenium levels in the heart, and 4-PBA and TUDCA maintained the selenium in the liver, kidney, and muscle at normal. At 2 months, 4-PBA and TUDCA maintained the selenium in the heart, liver, and kidney at normal levels. The serum selenium had a positive correlation with zinc and copper in the diabetes group and the control group, while the serum selenium had no significant association with magnesium and calcium at 2 weeks and 2 months. TUDCA and 4-PBA have crucial effects on selenium distribution in diabetic mice, and further research is needed to research their internal mechanisms.

Endoplasmic Reticulum Dysfunction: An Emerging Mechanism of Vitiligo Pathogenesis

“…It was reported that 4-PBA could alleviate hyperoxia-induced acute lung injury 89 and rescue hyperoxaluria-induced nephrolithiasis by modulating urinary glycoproteins. 90 In addition, TUDCA and 4-PBA have crucial effects on selenium distribution in diabetic mice 91 and they also block ER stress in post-ischemic kidneys. 92 Moreover, a study of gut microbial dysbiosis and plasma metabolic in vitiligo detected an abnormal level of TCDCA, an upstream metabolite of TUDCA.…”

Emerging Anti-Diabetic Drugs for Beta-Cell Protection in Type 1 Diabetes

“…The relation of selenium and diabetes is controversial, but a study showed that selenium helps in reducing diabetes because it exhibits antioxidant and anti-inflammatory properties [48,49]. Besides reducing the oxidative stress, TUDCA showed a promising result in the selenium distribution in the liver, kidney, heart, and muscle of type 1 diabetic mice, and was also found to be effective in blood glucose levels of mice [50]. These studies concluded that TUDCA is a potential therapeutic agent for the protection of beta cells as well as in insulin stimulation [51].…”